Aarti Drugs (NSE:AARTIDRUGS) Beneish M-Score: -2.48 (As of Jun. 30, 2026)


NSE:AARTIDRUGS Aarti Drugs Ltd NSE:AARTIDRUGS
75 GF Score
Price ₹373.45
GF Value ₹497.01
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aarti Drugs Beneish M-Score?

Aarti Drugs NSE:AARTIDRUGS +0.20% 75 Beneish M-Score is -2.48 as of Jun. 30, 2026. GuruFocus rates NSE:AARTIDRUGS with a GF Score™ of 75/100 and a GF Value™ of ₹497.01 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 908 Drug Manufacturers companies, Aarti Drugs ranks worse than 51.87% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.48 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Aarti Drugs's Beneish M-Score or its related term are showing as below:

NSE:AARTIDRUGS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.96   Med: -2.47   Max: -1.78
Current: -2.48

During the past 13 years, the highest Beneish M-Score of Aarti Drugs was -1.78. The lowest was -2.96. And the median was -2.47.


Aarti Drugs Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Aarti Drugs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Drugs Beneish M-Score Chart

Aarti Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.78 -1.79 -2.87 -2.65 -2.48

Aarti Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.65 0.00 0.00 0.00 -2.48

NSE:AARTIDRUGS vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Beneish M-Score falls into.


NSE:AARTIDRUGS
75GF Score
Aarti Drugs Ltd NSE:AARTIDRUGS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Drugs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aarti Drugs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0113+0.528 * 0.9593+0.404 * 0.6742+0.892 * 1.0747+0.115 * 0.9331
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.020822-0.327 * 0.9613
=-2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹8,306 Mil.
Revenue was ₹25,653 Mil.
Gross Profit was ₹9,466 Mil.
Total Current Assets was ₹14,678 Mil.
Total Assets was ₹28,153 Mil.
Property, Plant and Equipment(Net PPE) was ₹12,838 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹670 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹9,223 Mil.
Long-Term Debt & Capital Lease Obligation was ₹2,577 Mil.
Net Income was ₹1,949 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹2,535 Mil.
Total Receivables was ₹7,642 Mil.
Revenue was ₹23,870 Mil.
Gross Profit was ₹8,449 Mil.
Total Current Assets was ₹13,384 Mil.
Total Assets was ₹25,747 Mil.
Property, Plant and Equipment(Net PPE) was ₹11,499 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹558 Mil.
Selling, General, & Admin. Expense(SGA) was ₹849 Mil.
Total Current Liabilities was ₹8,370 Mil.
Long-Term Debt & Capital Lease Obligation was ₹2,857 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(8305.7 / 25653.1) / (7642.037 / 23870.3)
=0.32377 / 0.320148
=1.0113

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8449.3 / 23870.3) / (9465.9 / 25653.1)
=0.353967 / 0.368996
=0.9593

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (14677.7 + 12837.8) / 28152.6) / (1 - (13383.55 + 11499.059) / 25746.782)
=0.02263 / 0.033564
=0.6742

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=25653.1 / 23870.3
=1.0747

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(557.8 / (557.8 + 11499.059)) / (669.7 / (669.7 + 12837.8))
=0.046264 / 0.04958
=0.9331

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 25653.1) / (849.38 / 23870.3)
=0 / 0.035583
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2577.3 + 9222.6) / 28152.6) / ((2856.507 + 8369.668) / 25746.782)
=0.419141 / 0.436022
=0.9613

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1949.2 - 0 - 2535.4) / 28152.6
=-0.020822

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aarti Drugs has a M-score of -2.48 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.48 mean?
Aarti Drugs (NSE:AARTIDRUGS) has a Beneish M-Score of -2.48 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aarti Drugs and its competitors. According to the industry distribution chart, Aarti Drugs ranks #471 out of 908 companies in the Drug Manufacturers industry, placing it in the top 51.9%.
Is Aarti Drugs' Beneish M-Score too high?
Aarti Drugs' current Beneish M-Score is -2.48. Based on the distribution chart, Aarti Drugs ranks #471 out of 908 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aarti Drugs has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aarti Drugs ranks #471 out of 908 companies for Beneish M-Score. This places Aarti Drugs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aarti Drugs and its competitors. Aarti Drugs's current Beneish M-Score is -2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹497.01, compared to a current price of ₹373.45 — trading 24.9% below its estimated fair value. The current Beneish M-Score is -2.48. Aarti Drugs' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current Beneish M-Score is -2.48 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued. The current stock price of ₹373.45 is trading 24.9% below its estimated GF Value™ of ₹497.01. GuruFocus considers Aarti Drugs to be Modestly Undervalued.

Key valuation signals for NSE:AARTIDRUGS:

  • Beneish M-Score: -2.48
  • GF Value™: ₹497.01 vs. price of ₹373.45 (24.9% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarti Drugs Business Description

Other Exchanges 524348:India
Address Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
75GF Score

Get the complete analysis for NSE:AARTIDRUGS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹373.45
Price
₹497.01
GF Value